TAK1 Inhibitor Enhances the Therapeutic Treatment for Glioblastoma

TAK1 Inhibitor Enhances the Therapeutic Treatment for Glioblastoma

Glioblastoma (GBM) is a brain tumor characterized by poor therapeutic response and overall survival. Despite relevant progress in conventional treatments represented by the clinical use of temozolomide (TMZ), a combination of approaches might be a possible future direction for treating GBM. Transfor...

Full description

Bibliographic Details
Main Authors: Michela Campolo, Marika Lanza, Giovanna Casili, Irene Paterniti, Alessia Filippone, Maria Caffo, Salvatore M. Cardali, Ivana Puliafito, Cristina Colarossi, Gabriele Raciti, Salvatore Cuzzocrea, Emanuela Esposito
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
TAK1
temozolomide
glioblastoma
cell lines
patients
Online Access:https://www.mdpi.com/2072-6694/13/1/41

Internet

https://www.mdpi.com/2072-6694/13/1/41

Similar Items